论文部分内容阅读
[目的]评价卵巢癌患者外周血淋巴细胞亚群表达与预后相关性。[方法]流式细胞仪检测55例卵巢癌患者的临床病理资料和治疗前的外周血淋巴细胞亚群(CD4+,CD8+,CD4+/CD8+,CD56+,CD44+)的表达水平,随访肿瘤患者预后。统计学分析采用SPSS16.0统计软件,不同临床病理参数下淋巴细胞亚群水平比较作t检验或F检验,生存率分析采Kaplan-Meier法和Log-Rank检验。[结果]不同分化程度、临床分期间患者淋巴细胞亚群的5项指标均无统计学差异(P>0.05)。但CD4+/CD8+比值与年龄相关。CD8+细胞比例正常者的中位生存时间为46个月,而CD8+细胞比例异常者的中位生存时间为26个月(χ2=6.475,P=0.011)。[结论]卵巢癌患者血清淋巴细胞亚群中CD8+和CD4+/CD8+比值可作为卵巢癌预测患者预后的因子之一。
[Objective] To evaluate the correlation between peripheral blood lymphocyte subsets and prognosis in patients with ovarian cancer. [Methods] The clinical and pathological data of 55 cases of ovarian cancer and the level of peripheral blood lymphocyte subsets (CD4 +, CD8 +, CD4 + / CD8 +, CD56 +, CD44 +) were detected by flow cytometry. The prognosis of the patients was followed up. Statistical analysis using SPSS16.0 statistical software, different clinical pathological parameters of lymphocyte subsets compared to t test or F test, survival analysis Kaplan-Meier method and Log-Rank test. [Results] There were no significant differences in all five indicators of lymphocyte subsets between different degrees of differentiation and clinical stage (P> 0.05). However, the CD4 + / CD8 + ratio is age-related. The median survival time of CD8 + cells was 46 months, while the median survival time of CD8 + cells was 26 months (χ2 = 6.475, P = 0.011). [Conclusion] The ratio of CD8 + and CD4 + / CD8 + in serum lymphocyte subsets of ovarian cancer patients may be one of the prognostic factors in ovarian cancer patients.